We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Trillium Therapeutics Inc | NASDAQ:TRIL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 18.44 | 20.33 | 18.30 | 0 | 01:00:00 |
From Jul 2019 to Jul 2024
TTI-622: Poster Presentation, Publication Number 1191Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation StudyPresenter: Krish Patel, M.D., Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WASession: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials: Poster IDate: Saturday, December 5, 2020; available from 10:00AM EST
TTI-621: Oral Presentation, Publication Number 646Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic MalignanciesPresenter: Steven M. Horwitz, M.D., Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NYSession: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Immunotherapy in T/NK Cell LymphomaDate: Monday, December 7, 2020; Presentation at 3:00PM EST
The presentations will be available in the Events & Presentations section of Trillium’s website once released by the American Society of Hematology.
Trillium will host a conference call on Monday, December 7th at 4:30PM EST.
International Dial-In Number: +1 236-389-2162Conference ID: 3169183
Webcast link: https://event.on24.com/wcc/r/2862177/A91BDB88D738527918C13E289B26CED7
About Trillium Therapeutics Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.
For more information visit: www.trilliumtherapeutics.com
Investor Relations:James ParsonsChief Financial OfficerTrillium Therapeutics Inc. 416-595-0627 x232james@trilliumtherapeutics.com www.trilliumtherapeutics.com
Media Relations:Mike BeyerSam Brown Inc.312-961-2502mikebeyer@sambrown.com
1 Year Trillium Therapeutics Chart |
1 Month Trillium Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
